The DEA has signaled a fourth extension of telemedicine flexibilities for prescribing controlled substances, pushing the deadline into 2026. This move preserves uninterrupted patient access while giving clinicians, pharmacists and health system leaders more time to prepare for the agency’s forthcoming long-term rules.
Read More